MAPT and Alzheimer disease: Advancements in research, particularly in targeting the underlying mechanisms such as advanced glycation end products (AGEs), amyloid plaques, tau phosphorylation, and neuroinflammation, are crucial for developing treatments that can slow or prevent the onset of AD 2.